Zalicus
SITE MAP   |   CAREERS   |   CONTACT   |   
Company OverviewProduct PipelineDiscovery TechnologiesInvestors and Media
What we do

Zalicus discovers and develops treatments for pain and immuno-inflammatory diseases. Our pipeline includes Exalgo™ for moderate to severe pain, Synavive®, for rheumatoid arthritis, Z160, an N-type calcium channel blocker for chronic inflammatory and neuropathic pain and Z944, a T-type calcium channel blocker for acute and inflammatory pain. Learn More

Who we are

Zalicus discovers and develops innovative therapeutics for patients in need. We believe that our novel product candidates, productive drug discovery platforms, drug development expertise, revenue-generating collaborations and financial resources provide a solid foundation for success. Learn More

News and events      Get RSS (What's this?)

05/09/12

Zalicus to Present at Two Upcoming Investor Conferences More

 

05/03/12

Zalicus Reports Financial Results for the First Quarter 2012 More

 

05/02/12

Zalicus Advancing Z160, Its Novel, Oral N-type Calcium Channel Blocker, into Multiple Phase 2a Clinical Trials for the Treatment of Pain More